NCT05038696View on ClinicalTrials.gov

ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

May 1, 2026

Study Completion Date

August 1, 2026

Conditions

Lymphoblastic Leukemia, Acute, ChildhoodLymphoblastic LeukemiaLymphoblastic Leukemia, Acute AdultLymphoblastic Leukemia in ChildrenCARCAR T-Cell-Related Encephalopathy Syndrome

Interventions

BIOLOGICAL

CAR T-cell therapy

This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk B-ALL, refractory or relapsed B-ALL.

Trial Locations (1)

119228

RECRUITING

Allen Yeoh Eng Juh, Singapore

All Listed Sponsors

lead

National University Hospital, Singapore

OTHER

NCT05038696 - ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. | Biotech Hunter | Biotech Hunter